Stocks and Investing
Stocks and Investing
Thu, September 27, 2012
[ 07:42 AM ] - WOPRAI
[ 07:42 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:41 AM ] - WOPRAI
[ 07:40 AM ] - WOPRAI
[ 07:40 AM ] - WOPRAI
[ 07:40 AM ] - WOPRAI
[ 07:40 AM ] - WOPRAI
[ 07:31 AM ] - Market Wire
[ 05:45 AM ] - Market Wire
[ 05:40 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Cory Kasimov Maintained (BMRN) at Buy with Increased Target to $50 on, Sep 27th, 2012
Cory Kasimov of JP Morgan, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $47 to $50 on, Sep 27th, 2012.
Cory has made no other calls on BMRN in the last 4 months.
There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 1 agrees with Cory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Andrew Peters of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $45 on, Monday, August 27th, 2012
These are the ratings of the 2 analyists that currently disagree with Cory
- Gena Wang of "Barclays" Initiated at Buy and Held Target at $46 on, Friday, August 24th, 2012
- Matthew Harrison of "Morgan Stanley" Maintained at Strong Buy with Increased Target to $52 on, Monday, July 23rd, 2012